Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.19
$17.03M1.19171,481 shs4.12 million shs
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
$10.75
-0.3%
$10.76
$10.20
$11.30
$156.52M-0.01121,140 shs3,300 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$8.62
$6.39
$3.85
$9.06
$692.70M1.24406,711 shs400,903 shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.70
+2.2%
$4.77
$0.53
$5.25
$47.32M-1.668,920 shs2,447 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%+0.62%-72.22%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.00%0.00%0.00%0.00%0.00%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-0.58%0.00%+36.18%+59.33%+72.75%
OpGen, Inc. stock logo
OPGN
OpGen
+2.17%+3.30%-3.69%+12.71%+50.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
4.1941 of 5 stars
3.51.00.04.82.72.50.6
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.00
N/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3.00
Buy$24.00178.42% Upside
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HHLA, OPGN, ENZ, and MGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $35.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/A$1.71 per share6.29($1.19) per shareN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$33.28M20.81N/AN/A$0.87 per share9.91
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M17.70N/AN/A($11.55) per share-0.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
$17.69M-$0.14N/AN/AN/A-57.47%-0.35%N/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$147.79M-$2.32N/A22.68N/A-484.90%-241.05%-62.93%8/11/2025 (Estimated)
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%N/A

Latest HHLA, OPGN, ENZ, and MGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.52N/AN/AN/A$8.00 millionN/A
5/13/2025Q1 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/A
0.03
0.03
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.34
1.53
1.51
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45

Institutional Ownership

CompanyInstitutional Ownership
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
39.24%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%

Insider Ownership

CompanyInsider Ownership
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.54%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/A14.56 million14.48 millionNot Optionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30080.36 million74.34 millionOptionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable

Recent News About These Companies

OpGen Forms Joint Venture with European Bank
OpGen Appoints New COO and Company Secretary
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
OpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock Split
OpGen Announced 1-for-10 Reverse Stock Split

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

HH&L Acquisition stock logo

HH&L Acquisition NYSE:HHLA

HH&L Acquisition Co. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on healthcare or healthcare-related companies in Asian markets. HH&L Acquisition Co. was incorporated in 2020 and is based in Central, Hong Kong.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$8.62 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$8.62 0.00 (0.00%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.70 +0.10 (+2.17%)
As of 07/17/2025 03:37 PM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.